Key result
ACS is linked to higher serum resistin and prooxidant-antioxidant balance versus stable CHD.
Why the study?
Resistin and oxidative stress may contribute to the pathogenesis of coronary heart disease, but their role in ACS occurrence and ability to differentiate it from stable angina remained to be investigated.
Do serum resistin and prooxidant-antioxidant balance (PAB) levels differentiate acute coronary syndrome from stable coronary heart disease?
Cross-Sectional (n=100)
Do serum resistin and prooxidant-antioxidant balance (PAB) levels differentiate acute coronary syndrome from stable coronary heart disease?
High serum resistin and PAB levels are significantly associated with acute coronary syndrome and may serve as biomarkers to differentiate it from stable coronary heart disease.
Answers are grounded in this paper and cite their sources.
Elevated resistin and PAB were associated with ACS versus stable CHD; leaves open their added value for differentiation beyond hs-CRP in prospective studies.
BACKGROUND: Resistin and oxidative stress may play a role in the pathogenesis of coronary heart disease (CHD) including acute coronary syndrome (ACS). The aim of this study was to investigate the role of serum resistin and prooxidant-antioxidant balance (PAB) in ACS occurrence in order to differentiate it from stable angina. Moreover, we aimed to determine the correlation between resistin and PAB in patients with ACS and its difference from patients with stable CHD. METHODS: This cross-sectional, descriptive study was conducted on 50 patients with ACS and 50 patients with stable CHD who underwent coronary angiography (CAG). Serum resistin level was measured using enzyme-linked immunosorbent assay (ELISA). PAB and other variables were analyzed using standard methods. RESULTS: A significant increase in serum resistin and PAB was observed in patients with ACS (2.55 ± 0.13 ng/ml and 123.5 ± 5.58 HK unit, respectively) compared to patients with stable CHD (1.53 ± 0.12 ng/ml and 95.9 ± 2.7 HK unit, respectively) (P < 0.001). In addition, a significant positive correlation was seen between serum resistin and PAB in patients with ACS (r = 0.39; P = 0.005), but this correlation was not found in patients with stable CHD (r = 0.21; P = 0.140). Resistin (r = 0.52; P < 0.001) and PAB (r = 0.55; P < 0.001) were significantly associated with high-sensitivity C-reactive protein (hs-CRP) in patients with ACS, but this association was not found in patients with stable CHD (resistin: r = 0.24; P = 0.090; PAB: r = -0.02: P = 0.910). CONCLUSION: High serum resistin or PAB levels, and their association with the occurrence of ACS, can be used as a robust discriminating factor to differentiate ACS from stable CHD.
No takes yet. Share an insight, caveat, or question.
Pourmoghaddas et al. (2020) conducted a cross-sectional in Acute coronary syndrome and stable coronary heart disease (n=100). Acute coronary syndrome vs. Stable coronary heart disease was evaluated on Serum resistin level (ng/ml) (p=<0.001). Serum resistin (2.55 vs 1.53 ng/ml) and prooxidant-antioxidant balance (123.5 vs 95.9 HK unit) were significantly higher in patients with ACS compared to stable CHD (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: